Clinical Outcomes of Risankizumab for Moderate-to-Severe Crohn's Disease: A Real-World Study From Taiwan (STAR Trial)

Authors
Category Primary study
ConferenceAsian Pacific Digestive Week, APDW
Year 2026
This article has no abstract
Epistemonikos ID: b13f7faa4f176d25b5be5c50b25002de40b9c913
First added on: May 18, 2026